<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896359</url>
  </required_header>
  <id_info>
    <org_study_id>HUBI - 14539</org_study_id>
    <nct_id>NCT04896359</nct_id>
  </id_info>
  <brief_title>High Doses Vitamin C and Tissular Repair in Surgical Patients</brief_title>
  <official_title>Effect of High Doses of Vitamin C on the Tissular Reparation (Healing) in Patients Under Surgery in the &quot;Hospital de Los Valles&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad San Francisco de Quito</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomolec Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad San Francisco de Quito</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomize, double-blind, and placebo-controlled study to evaluate in&#xD;
      patients with clinical criteria for any of the following open surgical procedure: (1)&#xD;
      cesarean section; (2) aesthetic surgery like abdominoplasty; (3) orthopedic surgery; and (4)&#xD;
      abdominal open surgery [excluding laparoscopic procedures] will be invited to receive either&#xD;
      a high dose of vitamin C (12.5 g) three times (48 h pre-surgery, immediately before surgery&#xD;
      and 48 h post-surgery) or its placebo, to evaluate the tissue repair process using an&#xD;
      international validated instrument named Patient and Observer Scar Assessment Scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Actual">March 3, 2021</completion_date>
  <primary_completion_date type="Actual">March 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of linear scars</measure>
    <time_frame>initial assessment, two weeks after surgery</time_frame>
    <description>Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of linear scars</measure>
    <time_frame>second assessment, one month after surgery</time_frame>
    <description>Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of linear scars</measure>
    <time_frame>third assessment, three months after surgery</time_frame>
    <description>Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Tissue Damage</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>12.5 grams of ascorbic acid</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>vehicle</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years.&#xD;
&#xD;
          -  Susceptible for any of the following surgical procedures: (1) cesarean section; (2)&#xD;
             aesthetic abdominal plastic surgery; (3) orthopedic prosthetic replacement surgery&#xD;
&#xD;
          -  Voluntary consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to the vitamin C&#xD;
&#xD;
          -  Known problems with wounds healing&#xD;
&#xD;
          -  Kidney disease (including lithiasis) or gout&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Teran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad San Francisco de Quito</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de los Valles</name>
      <address>
        <city>Quito</city>
        <state>Pichincha</state>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ecuador</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad San Francisco de Quito</investigator_affiliation>
    <investigator_full_name>Enrique Teran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

